ICIs may restore the ability of cancer immunity to kill tumor cells by blocking some inhibitory molecules of “immune checkpoints” such as PD-1, PD-L1, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [60]. This evidence concerns the gene CD274 and cancer.